The pharmacoeconomic evaluation exemption system has received unflattering attention since its implementation. It is no wonder that the government has been gathering voices in support of its 'reduction' under the pretense of 'improvement'.

The PE exemption system is the only system in Korea's insurance policy landscape that helps patients with rare diseases and rare cancers get the treatments they need.

Applying double pricing through risk-sharing agreements (RSAs) and other measures has also contributed to reducing barriers and improving access to new drugs, but the PE exemption system has made otherwise impossible acceptance possible.

But always, the government has to wo